# StrideBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stridebio

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.stridebio.com
- Total disclosed funding: $65M
- Latest round: Series B (Mar 16, 2021)
- Investors on record: 11

## About

Based in the US, StrideBio, Inc. is a biotechnology firm focused on developing innovative gene therapies targeting life-threatening genetic disorders using their proprietary technology.StrideBio, Inc. specializes in gene therapy development, particularly utilizing their STRIVE™ Capsid Platform. Founded in 2015 in Durham, US, the company was established by Aravind Asokan and has since conducted 4 total deals. The most recent funding was achieved during the SERIES B round in April 2023, raising USD 48.92 mn from a consortium of investors including CaaS Capital Management and Novo Holdings. The company is currently valued at USD 158.15 mn.StrideBio develops advanced gene therapies that focus on life-threatening diseases. Their main offerings involve innovative gene therapy products based on the STRIVE™ Capsid Platform, which enhances the delivery of adeno-associated virus (AAV) vectors. The company also possesses advanced AAV manufacturing capabilities, ensuring high-quality production standards. StrideBio collaborates primarily with pharmaceutical partners and research institutions across North America and Europe, aiming to improve outcomes for patients with rare genetic disorders.StrideBio generates revenue through strategic partnerships and collaborations with pharmaceutical companies interested in its gene therapy technologies. Their business model centers around B2B transactions, often involving contracts with milestone payments and royalties based on successful product commercialization. The therapeutic products offered by StrideBio are integral to these partnerships, aligning the financial success of both StrideBio and its collaborators as they advance towards market entry.StrideBio's strategy includes utilizing recent funding to enhance its gene therapy product pipeline and expand its reach into new global markets. Following the acquisition of its AAV Capsid Discovery and Engineering Platform Assets by Ginkgo BioWorks, Inc. in April 2023, the company will focus on launching new products that target previously unmet medical needs. Future plans also involve extending partnerships and collaborations aimed at geographical expansion into Asia by 2025, further bolstering their therapeutic offerings in the global market.

## Funding rounds

- Series B, Mar 16, 2021, $49M — Hatteras Venture Partners, Pontifax Venture Capital, Takeda Ventures, Novo Holdings, UCB Ventures, Northpond Ventures, Sarepta Therapeutics, Inc., Octagon Capital Advisors, CaaS Capital Management, UF Innovate Ventures
- Series A, Jun 13, 2018, $16M — Alexandria Venture Investments, Hatteras Venture Partners, Takeda Ventures, UCB Ventures
- Seed, May 30, 2017 — Hatteras Venture Partners

## Investors

- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Seed, Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A, Series B
- UCB Ventures (https://capitalatlas.ai/funds/ucb-ventures) — Series A, Series B
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series B
- Novo Holdings — Series B
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series B
- Sarepta Therapeutics, Inc. — Series B
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series B
- CaaS Capital Management (https://capitalatlas.ai/funds/caas-capital-management) — Series B
- UF Innovate Ventures (https://capitalatlas.ai/funds/uf-innovate-ventures) — Series B